IL2 and type 1 diabetes mellitus: Notably protective IL2 alleles were linked to increased regulatory T cell frequency and mucin production within the intestine and IL2 therapy could mimic this effect on the gut suggesting that immunotherapy outcomes in T1D may also be linked to the gut microbiota response (40, 41).